Seer, Inc.

Seer, Inc. is an American biotechnology company headquartered in Redwood City, California, founded in 2017. The company's core mission is to transform proteomics research by overcoming technological barriers to studying the proteome, thereby empowering scientists to achieve breakthroughs in understanding complex biology and discovering biomarkers to improve human health. [1, 2, 3, 11]

Seer specializes in developing and commercializing proteomics technologies, primarily its proprietary Proteograph Product Suite. This integrated solution includes engineered nanoparticles, consumables, automation instrumentation, and advanced data analysis software, designed to enable unbiased, deep, and scalable analysis of the proteome. [1, 3, 18, 19, 33] The company also offers custom proteomics services and operates Seer Technology Access Centers (STACs) in Redwood City, California, and Bonn, Germany. [2, 3, 29] Seer targets academic and research institutions, pharmaceutical and biotechnology companies, government entities, and contract research organizations, with applications spanning disease detection, drug discovery, and biomarker research for conditions such as cancer and neurological disorders. [1, 2, 3, 18, 22]

Omid C. Farokhzad, M.D., Ph.D., serves as the co-founder, Chair, and Chief Executive Officer. [1, 2, 3, 6, 7, 10, 18] Recent notable developments include ongoing unsolicited acquisition proposals from the Radoff-JEC Group, which Seer's Board of Directors has rejected, citing undervaluation. [8, 13, 16, 19, 24] The company has also expanded its reach through collaborations, such as a partnership with Precision Health Research, Singapore, to conduct deep proteomics on 10,000 samples. [12, 13, 16] Seer continues to advance its technology, having launched an updated Proteograph workflow in May 2025, featuring the Proteograph ONE Assay and SP200 Automation Instrument, designed for high-throughput processing. [1, 2]